title: A randomized trial and the treatment of pemphigus vulgaris.
abstract: Pemphigus vulgaris is a rare, life-threatening autoimmune disease. Mycophenolate mofetil is a potent immunosuppressant medication approved by the Food and Drug Administration to be used after solid organ transplantation and to treat pemphigus vulgaris. Mycophenolate mofetil has not become the "wonder drug" that had been anticipated based on initial clinical reports. Studies like that reported by Beissert et al. in this issue are essential to improve dermatologic care.
authors.affiliation: Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. margo@mail.med.upenn.edu
authors.forename: David J
authors.initials: DJ
authors.lastname: Margolis
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010392:Pemphigus / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid